In this interview, NewsMedical speaks with Jeff Hawkins, CEO of Quantum-Si, about the challenges of conventional proteomic methods, as well as how next-generation protein sequencing is democratizing protein sequencing.
Topical JAK Inhibitor Active in Itchy Prurigo Nodularis
ORLANDO — More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura), according to